H122 results highlight @RedxPharma pipeline progress. Cash (incl recent c £34m equity raise) + modest risk-adj milestones provides runway thru end-2023, comfortably supporting Phase II plans for #RXC004 in #oncology & #RXC007 in #fibrosis. $REDX #REDX https://www.trinitydelta.org/companies/redx-pharma/

Continued momentum for ANGLE’s @Parsortix Pharma Services offering with an additional contract owing to trial progression with an existing customer. New contract is worth up to $1.2m and highlights the growth potential of this relatively nascent business opportunity. $AGL #AGL

Top 5 global pharma collab is more evidence of the value of @arecor_plc’s #formulation expertise & broad applicability of its #Arestat platform to a range of therapeutic products, w/ the growing tech partnerships portfolio a source of potential future licence deals. #AREC $AREC

Milestone from $JAZZ on IND approval for pan-RAF JPZ815 boosts @RedxPharma's cash pile and demonstrates continued progress across a broad range of programmes stemming from Redx’s well proven medicinal chemistry expertise. For more on $REDX:

https://www.trinitydelta.org/companies/redx-pharma/

First-patient dosed in @scancellpharma’s Phase I trial of Modi-1, the lead programme from the #Moditope platform. This is a key step towards valuable early data from H222. For more on #SCLP $SCLP:
https://www.trinitydelta.org/companies/scancell/

Quality of @RedxPharma's equity story is starting to be appreciated as existing & new specialist investors support a £34.3m (gross) oversubscribed raise at no discount in a tough market. Cash runway extends thru key data points in 2023. For more on $REDX: https://www.trinitydelta.org/companies/redx-pharma/